Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease by Joshua J. Field, Elaine Majerus, Victor R. Gordeuk, Michel Gowhari, Carolyn Hoppe, Matthew M. Heeney, Maureen Achebe, Alex George, Hillary Chu, Brian Sheehan, Maneka Puligandla, Donna Neuberg, Gene Lin, Joel Linden, and David G. Nathan BloodAdv Volume 1(20):1645-1649 September 12, 2017 © 2017 by The American Society of Hematology

Joshua J. Field et al. Blood Adv 2017;1:1645-1649 © 2017 by The American Society of Hematology

Subject flow through the study. Joshua J. Field et al. Blood Adv 2017;1:1645-1649 © 2017 by The American Society of Hematology

Baseline vs end-of-infusion p65-phospho NF-κB iNKT cell activation. Baseline vs end-of-infusion p65-phospho NF-κB iNKT cell activation. Points below the black line represent patients who achieved the primary outcome measure of a p65-phospho-NF-κB iNKT cell activation at 48 hours that was a >30% reduction from baseline. Subjects in the regadenoson and placebo arms are represented by red and white circles, respectively. Joshua J. Field et al. Blood Adv 2017;1:1645-1649 © 2017 by The American Society of Hematology